drugset / Trial / NCT05322070

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070

Phase 4 Active not recruiting 125 enrolled Alimera Sciences CBCC Global Research · collab
NaSingle-groupOpen-labelTreatment

Summary

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

Timeline

Start
2022-06-06
Primary completion
2025-11
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Subject fluocinolone acetonide Small molecule 0.18 mg Intravitreal

Indications